Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00717808Phase 1Withdrawn

Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)

Role: collaborator

NCT01109121Phase 2Completed

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

Role: lead

NCT00995618Phase 2Completed

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

Role: lead

NCT00882024Phase 2Completed

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

Role: lead

NCT01052987Phase 2Completed

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

Role: lead

All 5 trials loaded